Your session is about to expire
← Back to Search
NAC Eye Drops for Fuchs' Dystrophy
Study Summary
This trial will test whether N-acetyl cysteine eye drops can protect patients with FECD from oxidative stress.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I need surgery for a cornea transplant and cataract removal at the same time.I have a history of serious eye conditions affecting the cornea.I use eye medication, but only for dryness, swelling, or pressure.I am 21 years old or older.You have experienced negative reactions to using N-Acetylcysteine on your skin in the past.I have advanced Fuchs' dystrophy and a significant cataract affecting my vision.I am willing and able to follow the medication plan.I am willing and able to follow the medication plan.I am 21 years old or older.I have had eye surgery for cataract, glaucoma, or retina issues.I have not had an eye infection in the last 30 days.I haven't used N-Acetylcysteine in any form in the last 30 days.
- Group 1: NAC 20% group
- Group 2: Placebo group
- Group 3: NAC 10% group
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this research recruiting participants at present?
"As per the clinicaltrials.gov website, this trial is actively recruiting participants and has been since it was first posted on September 16th 2020 with its most recent update being October 5th 2021."
Has the regulatory body approved NAC 10% group for public use?
"NAC 10% has been awarded a safety index score of 2 due to the fact that there is only preliminary evidence indicating its security, but no data evaluating it's efficacy."
To what conditions is NAC 10% typically prescribed?
"NAC 10% group is a recommended treatment for parenteral nutrition, total amino acid supplementation therapy, and dry eyes."
Have any prior experiments been conducted using the NAC 10% cohort?
"At the time of this writing, 28 clinical trials are actively studying NAC 10% group with 7 being in Phase 3. Of these studies, a significant number are running out of Halifax, Nova Scotia but there is also support for participants at 55 other locations across the globe."
What is the cap on enrollment for this medical experiment?
"Affirmative. Per the clinicaltrials.gov listing, this trial is currently open for recruitment and was initially published on September 16th 2020. The last revision to the listing occurred October 5th 2021 and 45 patients need to be recruited from 1 site."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger